Stocktoria
Janux Therapeutics, Inc. JANX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-11
Janux Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M |
| R&D expense | $125.9M | $68.4M | $54.9M | $53.4M | $26.2M |
| Operating income | -$157.7M | -$98.8M | -$73.0M | -$67.1M | -$32.9M |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | -$113.6M | -$69.0M | -$58.3M | -$63.1M | -$32.7M |
| EPS (diluted) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 |
| Operating cash flow | -$82.2M | -$43.8M | -$50.6M | -$42.9M | -$17.0M |
| Free cash flow | -$83.3M | -$44.2M | -$52.4M | -$49.4M | -$18.5M |
| Cash & equivalents | $52.3M | $430.6M | $19.2M | $51.4M | $35.6M |
| Total assets | $1.0B | $1.1B | $380.4M | $364.0M | $379.8M |
| Total liabilities | $44.7M | $38.7M | $36.1M | $43.3M | $13.5M |
| Shareholders' equity | $956.8M | $1.0B | $344.3M | $320.7M | $366.3M |
Source: SEC EDGAR filings · CIK 0001817713 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.